Status:
RECRUITING
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
Lead Sponsor:
Seoul National University Hospital
Conditions:
Neuromuscular Blockade
Critical Illness
Eligibility:
All Genders
19-90 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to compare the effect of use of reversal agents for neuromuscular blockade in critically ill patients on time for neurological assessment after endotracheal intubati...
Detailed Description
Patients who agree to participate in the study will be randomized to the sugammadex group, neostigmine group, or control group. Randomization will be performed by an independent investigator. Patient...
Eligibility Criteria
Inclusion
- Adult patients 19 years of age or older who were intubated after admission to the intensive care unit.
Exclusion
- Patients younger than 19 years of age
- Patients who are not neurologically evaluable or have concomitant neurologic dysfunction
- Patients with neuromuscular disorder
- Patients with a history of drug allergic reactions to sugammadex or neostigmine
- Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives
Key Trial Info
Start Date :
January 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05993390
Start Date
January 11 2024
End Date
August 30 2025
Last Update
June 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Jongno-gu, South Korea, 03080